Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial

AIDS

Volumn 17, Issue 9, 2003, Pages 1339-1349

  Haas, David W ^a,b   Zala, Carlos ^c   Schrader, Shannon ^d   Piliero, Peter ^e   Jaeger, Hans ^f   Nunes, Danilo ^g   Thiry, Alexandra ^h   Schnittman, Steven ^h   Sension, Michael ⁱ  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Comprehensive Care Center ^*  (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d Montrose Clinic   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f MUC Research GmbH and MVZ Karlsplatz   (Germany)

^g INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ North Broward Hospital   (United States)

Author keywords

Atazanavir; Highly active antiretroviral therapy; Metabolic changes; Protease inhibitors; Salvage therapy

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; BILIRUBIN; CD4 ANTIGEN; CHOLESTEROL; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLATULENCE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; INFECTIOUS COMPLICATION; JAUNDICE; LABORATORY TEST; LEUKOCYTE COUNT; LIPODYSTROPHY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZATION; RASH; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VOMITING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; MALE; OLIGOPEPTIDES; PILOT PROJECTS; PROTEASE INHIBITORS; PYRIDINES; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY; SAQUINAVIR; TREATMENT FAILURE;

EID: 0037661234     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200306130-00008     Document Type: Article

References (40)

1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://hivatis.org/trtgdlns.html. Accessed February 5, 2001.
2. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868.
3. Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS 2001; 15:201-209.
4. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
5. sgc, indinavir (IDV) or nelfinavir (NFV) in combination with amprenavir (APV), abacavir (ABC), efavirenz (EFZ) & adefovir (ADV) in patients (pts) with protease inhibitor (PI) failure [abstract LB7]. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January-February 2000. http://www.retroconference.org/2000/abstracts/lb7.htm. Accessed September 27, 2000.
6. Hogg RS, Yip B, Kully C, Craib KJP, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-665.
7. Montaner JSG, Mellors JW. Antiretroviral therapy for previously treated patients [editorial]. N Engl J Med 2001; 345:452-455.
8. Eron JJ, Jr. HIV-1 protease inhibitors. Clin Infect Dis 2000; 30(suppl 2):S160-S170.
9. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-F9.
10. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000; 44:2672-2678.
11. Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13:F23-F28.
12. Harris M, McNabb K, Harrigan R, Alexander C, Press N, O'Shaughnessy M, et al. Dual boosted protease inhibitor regimens: preliminary results in rescue therapy [abstract 685]. First International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001. http://www.ias.se/print.asp?abstract_id=685. Accessed March 4, 2003.
13. Montaner JSG, Harrigan PR, Jahnke N, Raboud J, Castillo E, Hogg RS, et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001; 15:61-69.
14. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999; 131:813-821.
15. Gallant JE. Strategies for long-term success in the treatment of HIV infection. JAMA 2000; 283:1329-1334.
16. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al for the Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000; 12:255-266.
17. Gong Y-F, Robinson B, Rose R, et al. Antiviral activity and resistance profile of an HIV-1 protease inhibitor BMS-232632 [abstract 1-79]. 38th Interscience on Antimicrobial Agents and Chemotherapy. San Diego, CA, September 1998. Conference Abstract Book. Herndon, VA: ASM Press; p.387.
18. Rabasseda X, Silvestre J, Castañer J. BMS-232632. Drugs of the Future 1999; 24:375-380.
19. Gong Y-F, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44:2319-2326.
20. Squires K, Gatell J, Piliero P, Sanne I, Wood R, Schnittman SM. AI424-007: 48-week safety and efficacy results from a phase II study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632 [abstract 15]. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001. http://www. retroconference.org/2001/abstracts/abstracts/abstracts/15.htm. Accessed March 4, 2003.
21. Sanne I, Piliero P, Wood R, Icelleher T, Cross A, Mangillo A, et al. Safety and antiviral efficacy of a once-daily HIV-1 protease inhibitor BMS-232632: 24 week results from a Phase II clinical trial [abstract 691]. 40th Interscience on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, September 2000. Abstracts Book. Herndon, VA: ASM Press; p. 292.
22. Sanne I, Piliero P, Wood R, Kelleher T, Cross A, Mongillo A, et al. Safety and antiviral efficacy of a novel once-daily HIV-1 protease inhibitor BMS-232632: preliminary results from a phase II clinical trial [abstract 672]. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January-February 2000. http://www.retroconference.org/2000/abstracts/672.htm. Accessed March 4, 2003.
23. O'Mara E, Mummaneni V, Randall D, Sagali N, Olsen S, Tanner T, et al. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract 504]. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January-February 2000. http://www.retroconference.org/2000/abstracts/504.htm. Accessed February 12, 2003.
24. O'Mara EM, Smith J, Olsen SJ, Tanner T, Schuster AE, Kaul S. BMS-232632: single and multiple oral dose safety and pharmacokinetic study in healthy volunteers [abstract 604]. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, IL, January-February 1999. http://www.retroconference.org/99/abstracts/604.htm. Accessed October 12, 2001.
25. Piliero P. The utility of inhibitory quotients in determining relative potency of protease inhibitors. AIDS 2002; 16:799-800.
26. Piliero PJ, Cahn P, Pantaleo G, Gatell J, Squires K, Percival L, et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile - results of clinical trials beyond week 48 [abstract 706-T]. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, WA,, February 2002. http://www.retroconference.org/2002/Abstract/13827.htm. Accessed February 12, 2003.
27. Cahn P, Percival L, Phanuphak P, Sanne I, Kelleher T, Giordano M. Phase II 24-week data from study AI424-008: comparative results of BMS-232632, stavudine, lamivudine as HAART for treatment-naïve HIV-infected patients [abstract 5]. First International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001. www.ias.se/abstract/show.asp?abstract_id=5. Accessed March 4, 2003.
28. Colonno R, Thiry A, Parkin NT. Amino acid substitutions that correlate with decreased susceptibility to atazanavir and other HIV-1 protease inhibitors. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, CA, September 2002 [abstract H2049]. www.icaac.org.
29. Harrigan PR, Hertogs K, Verbiest W, Pauwels R, Larder B, Kemp S, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863-1871.
30. O'Mara EM, Mummaneni V, Burchell B, Randall D, Geraldes M. Relationship between uridine diphosphate-glucuronosyl transferase (UDP-GT) 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, September 2000. [abstract 1645].
31. Zucker S, Qin X, Rouster S, Yu F, Green R, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98:12671-12676.
32. Kaplan M, Hammerman C, Rubaltelli FF, Vilei MT, Levy-Lahad E, Renbaum P, et al. Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism. Hepatology 2002; 35:905-911.
33. Pratt DS, Kaplan MM. Evaluation of liver function. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (editors): Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2002. pp. 1711-1715.
34. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
35. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999; 246:567-575.
36. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001; 15:725-734.
37. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-F70.
38. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000; 32:111-123.
39. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
40. Sanne I, Cahn P, Percival L, Phanuphak P, Kelleher TGM, Pantaleo G. Comparative results (phase II 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naïve HIV(+) patients (AI424-008) [abstract 1-667]. 41st Interscience on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2001. Abstract Book. Herndon, VA: ASM Press; p. 323.